Plasma Homocysteine in Patients with Retinal Vein Occlusion

Minniti, G.; Calevo, Maria Grazia; Giannattasio, A.; Camicione, Paola; Armani, U; Lorini, Renata; Piana, Gianna

doi:10.5301/ejo.5000426

Cited by 29 publications

(22 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to some studies, plasma tHcy levels inversely relate to the plasma vitamin B12 and folate concentrations [9,25,26]. So, higher plasma levels of folate and vitamin B12 in patients may neutralize the tendency to elevated plasma tHcy levels, subsequently reducing the risk for endothelial damage and RVT development [5,27].…”

Section: Discussionmentioning

confidence: 99%

Plasma homocysteine levels, methylene tetrahydrofolate reductase A1298C gene polymorphism and risk of retinal vein thrombosis

Ghaznavi

Soheili

Samiei

et al. 2016

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

There are limited data regarding the role of methylene tetrahydrofolate reductase (MTHFR) A1298C polymorphism and hyperhomocysteinemia as risk factors for retinal vein thrombosis (RVT) in Iranians. This study aimed to examine a possible association between fasting plasma total homocysteine (tHcy) levels, MTHFR A1298C polymorphism and RVT development in Iranian patients. Our study population consisted of 73 patients with a diagnosis of RVT (52.7 ± 16.2 years) and 73 age and sex-matched healthy controls (49.1 ± 14.6 years). Genotyping for the MTHFR A1298Cpolymorphism was conducted by PCR-RFLP technique and plasma tHcy levels were measured by an enzyme immunoassay method. Fasting plasma tHcy levels were 20.29 ± 8.5 μmol/l in RVT patients and 10.9 ± 3.1 μmol/l in control subjects. The number of cases with abnormal tHcy values (hyperhomocysteinemia) was significantly higher in the RVT patients than control subjects (P = 0.0001). The prevalence of MTHFR 1298CC homozygote genotype was similar in RVT patients and controls (17.8 vs.15.1%, P = 0.45). There were no significant differences in genotype distribution of MTHFR A1298C polymorphism between males and females in both RVT patients and controls (P > 0.05). The frequency of the 1298C allele was 39.1 and 35.6% in patients and controls, respectively, and did not differ significantly between them (P = 0.23). Moreover, heterozygote and homozygote genotypes in the RVT patients had significantly higher abnormal tHcy values than corresponding genotypes in control subjects (P < 0.001). Our study demonstrated that hyperhomocysteinemia but not homozygosity for MTHFR A1298C polymorphism is a significant risk factor for RVT in the Iranian population.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma homocysteine levels, methylene tetrahydrofolate reductase A1298C gene polymorphism and risk of retinal vein thrombosis

Ghaznavi

Soheili

Samiei

et al. 2016

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…Similar to neural degeneration, several retinal disorders have been associated with high levels of hcy. Elevated plasma hcy is a risk factor for retinal artery or vein occlusion, [11][12][13] and this condition is possibly improved by the intake of folate, vitamin B6, and vitamin B12 supplements, according to Martin et al 12 Hyperhomocysteinemia is also a main factor in the pathogenesis of retinal neuronal death, 14,15 diabetic retinopathy, 16 and even glaucoma. 17,18 However, the association between choroidal diseases and hcy levels has not yet been elucidated.…”

mentioning

confidence: 99%

Homocysteine Facilitates Prominent Polygonal Angiogenetic Networks of a Choroidal Capillary Sprouting Model

Lee

Chiu

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Citation: Lee Y-J, Chiu C-C, Ke C-Y, Tien N, Lin P-K. Homocysteine facilitates prominent polygonal angiogenetic networks of a choroidal capillary sprouting model. Invest Ophthalmol Vis Sci. 2017;58:4332-4343. DOI: 10.1167/iovs.17-22308 PURPOSE. To investigate the effects of homocysteine on choroidal angiogenesis, we established an ex vivo choroidal sprouting explant model and examined the potential growth factors for angiogenesis.METHODS. Choroid fragments with retinal pigment epithelium were isolated from mouse and embedded in Matrigel. Homocysteine at different concentrations were added to the culture mediums. The choroidal explants were observed at different time points, and the total area of choroidal sprouting was measured and analyzed.RESULTS. Homocysteine evoked choroidal capillary sprouting by inducing capillary endothelial cell proliferation with pericyte formation and by facilitating polygonal angiogenetic networks. In some cases, vascular lumens were observed in the newly forming capillaries facilitated by homocysteine. The choroidal sprouting effect of homocysteine can only be observed at a certain range of homocysteine concentration, with 1-mM homocysteine exhibiting the most significantly increased choroidal sprouting areas. Isolectin overexpression was noted in the homocysteine-treated group. Possible growth factors for angiogenesis were detected through immunofluorescent staining, which demonstrated the overexpression of platelet-derived growth factor C and angiopoietin 1 in the homocysteine-treated preparations only. In these preparations, platelet-derived growth factor C was highly expressed in the tip cells of sprouting capillaries.CONCLUSIONS. We therefore conclude that platelet-derived growth factor C and angiopoietin 1 may play key roles in the choroid angiogenesis evoked by homocysteine.

show abstract

“…Ocul Oncol Pathol 2020;6:159-163 DOI: 10.1159/000501155 A synergistic effect between coagulation disorders and the development of CRVO has been recognized; hypercoagulable workup can include testing for homocysteine and anticardiolipin antibodies, activated protein C resistance, and factor V Leiden testing [7][8][9]. A prospective case-control study found that patients with RVO were more likely to have hyperhomocysteinemia compared to controls [7], although some suggest that this is relevant to CRVO and not branch RVO [10]. Homocysteine is both atherogenic and prothrombotic and has been associated with a number of vascular events, including cerebrovascular, peripheral arterial, coronary heart disease, and venous thromboembolic disease [11,12].…”

Section: Discussionmentioning

confidence: 99%

MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants

et al. 2019

View full text Add to dashboard Cite

Central retinal vein occlusion (CRVO) is a rare side effect of MEK inhibitors. • MEK inhibitor-associated CRVO may result in permanent drug discontinuation. Novel Insights• MEK inhibitor-associated CRVO may be associated with hyperhomocysteinemia, suggesting a potential role for hyperhomocysteinemia screening prior to initiation of MEK inhibitor therapy. • In this small cohort, MEK inhibitor-associated CRVO was associated with good visual recovery following intravitreous anti-VEGF. AbstractBackground: Central retinal vein occlusion (CRVO) is a visually threatening event that has rarely been observed in patients taking MEK1/2 inhibitors and that may necessitate permanent discontinuation of a potentially efficacious therapy. We investigated the clinical characteristics of CRVO in patients on mitogen-activated protein kinase kinase (MEK) inhibition to better understand their predisposing factors and clinical course. Case Series: This was a single-center, ret-inhibitor-associated CRVO is a rare event which can exhibit visual recovery after drug cessation and intravitreous anti-VEGF injections. In this cohort, it was associated with hyperhomocysteinemia and genetic mutations in MTHFR, suggesting a potential role for hyperhomocysteinemia screening prior to initiation of MEK inhibitor therapy.

show abstract

Plasma Homocysteine in Patients with Retinal Vein Occlusion

Abstract: These results suggest that elevated fasting HCY levels, low vitamin B12 levels, and hypertension are associated with a risk of RVO, especially for CRVO. Moreover, our data suggest that only hypertension is associated with BRVO risk.

Cited by 29 publications

References 31 publications

Plasma homocysteine levels, methylene tetrahydrofolate reductase A1298C gene polymorphism and risk of retinal vein thrombosis

Plasma homocysteine levels, methylene tetrahydrofolate reductase A1298C gene polymorphism and risk of retinal vein thrombosis

Homocysteine Facilitates Prominent Polygonal Angiogenetic Networks of a Choroidal Capillary Sprouting Model

MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants

Contact Info

Product

Resources

About